XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
-0.01 (-0.73%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.35 - 1.41
52 week 0.69 - 5.95
Open 1.37
Vol / Avg. 0.00/6.38M
Mkt cap 161.59M
P/E     -
Div/yield     -
EPS -0.46
Shares 118.81M
Beta 3.46
Inst. own 43%
Dec 1, 2015
XOMA Corp at Piper Jaffray Healthcare Conference - 10:00AM EST - Add to calendar
Nov 19, 2015
XOMA Corp at Jefferies Autumn Global Healthcare Conference
Nov 11, 2015
XOMA Corp at Jefferies Energy Conference
Nov 5, 2015
Q3 2015 XOMA Corp Earnings Call - Webcast
Nov 5, 2015
Q3 2015 XOMA Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -23.14% -203.02%
Operating margin -1141.66% -433.75%
EBITD margin - -423.24%
Return on average assets -2.75% -34.17%
Return on average equity - -
Employees 171 -
CDP Score - -


2910 7th St
BERKELEY, CA 94710-2700
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Company's lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcet's disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcet's disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas M. Burns Chief Financial Officer
Bio & Compensation  - Reuters
James R. Neal Chief Operating Officer, Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Thomas Klein Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 88
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 80
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 62
Bio & Compensation  - Reuters